KATIA KHOURY

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology BIRMINGHAM, AL NPI 1013322445

General Payments — all program years on this page

$2,361.35

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 26
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $1,106.11 across 13 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Long term medical supply or device loan $999.9612
Food and Beverage $106.151

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $999.9612
Lilly USA, LLC $106.151

By program year

Program yearAmountRecords
2018 $184.802
2019 $116.601
2020 $98.101
2022 $347.344
2023 $508.405
2024 $1,106.1113

Records — PY2024 (13)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086984038 Novartis Pharmaceuticals Corporation $83.33 08/23/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984040 Novartis Pharmaceuticals Corporation $83.33 09/27/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984042 Novartis Pharmaceuticals Corporation $83.33 01/18/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984044 Novartis Pharmaceuticals Corporation $83.33 02/16/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984046 Novartis Pharmaceuticals Corporation $83.33 03/15/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984048 Novartis Pharmaceuticals Corporation $83.33 04/18/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984050 Novartis Pharmaceuticals Corporation $83.33 05/16/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984052 Novartis Pharmaceuticals Corporation $83.33 06/13/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984054 Novartis Pharmaceuticals Corporation $83.33 07/15/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984058 Novartis Pharmaceuticals Corporation $83.33 11/14/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984060 Novartis Pharmaceuticals Corporation $83.33 10/17/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086984062 Novartis Pharmaceuticals Corporation $83.33 12/10/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1135076869 Lilly USA, LLC $106.15 12/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.